Idiopathic thrombocytopenic purpura
Reading File
Finding Sources
Searching PubMed
"immune thrombocytopenia" AND treatment
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is the full clinical summary on ITP:
Idiopathic (Immune) Thrombocytopenic Purpura (ITP)
The term "idiopathic" has largely been replaced by "immune thrombocytopenia (ITP)" in current literature, reflecting its autoimmune etiology.
Definition
ITP is an acquired autoimmune disorder characterized by isolated thrombocytopenia (platelet count < 100 × 10⁹/L) in the absence of other identifiable causes. It involves both accelerated platelet destruction and impaired platelet production.
- Fischer's Mastery of Surgery, 8e
Pathophysiology
- Autoantibody production: IgG autoantibodies (mainly produced in the spleen) bind to platelet surface glycoproteins - primarily GPIIb/IIIa and GPIb-IX-V.
- Platelet destruction: Antibody-coated platelets undergo phagocytosis via Fcγ receptors on macrophages (predominantly in the spleen).
- Impaired megakaryopoiesis: Autoantibodies also impair platelet production by targeting megakaryocytes.
- T-cell role: CD4+ T cells expressing CD40 ligand activate and expand autoreactive T and B cells; the spleen acts as a reservoir for antiplatelet plasma cells - this is why splenectomy is therapeutically effective.
- Fischer's Mastery of Surgery, 8e; Roitt's Essential Immunology
Classification
| Type | Population | Features |
|---|---|---|
| Acute ITP | Children (typically < 5 years) | Follows viral infection; self-limiting; resolves spontaneously in > 70% |
| Chronic ITP | Adults (females aged 15-50 most affected) | Persists > 6 months; insidious onset; no identifiable cause |
- Bailey and Love's Short Practice of Surgery, 28e; Frameworks for Internal Medicine
Primary ITP = diagnosis of exclusion with no identifiable cause.
Secondary ITP = associated with SLE, CLL, Hodgkin's lymphoma, HIV, Hepatitis B/C, antiphospholipid syndrome, checkpoint inhibitor drugs.
Clinical Features
-
Skin: Petechiae, ecchymoses (purpuric patches), especially on pressure areas and lower extremities
-
Mucous membranes: Epistaxis, gingival bleeding, menorrhagia in women
-
Bleeding risk by platelet count:
-
50,000/mm³: mild bleeding (minor wounds, easy bruising)
- < 30,000/mm³: treatment generally indicated
- < 10,000/mm³: greatest risk for major internal/intracranial hemorrhage
-
-
Splenomegaly: Present in < 10% of patients; gross splenic enlargement should raise suspicion for an alternative diagnosis
-
Intracranial hemorrhage: Uncommon but is the most frequent cause of death
-
Bailey and Love's Short Practice of Surgery, 28e; Frameworks for Internal Medicine
Investigations
| Test | Finding |
|---|---|
| Complete blood count | Isolated thrombocytopenia (often < 60 × 10⁹/L); normal WBC and RBC |
| Peripheral blood smear | Large platelets; no schistocytes (important to exclude TTP) |
| Coagulation studies (PT, aPTT) | Normal |
| Bleeding time | Not helpful for diagnosis |
| Bone marrow aspiration | Increased/normal megakaryocytes (rules out aplastic anemia) |
| HIV, Hepatitis B/C serology | Mandatory to rule out secondary ITP |
| ANA / antiphospholipid antibodies | To exclude SLE/APS |
- Bailey and Love's Short Practice of Surgery, 28e; Fischer's Mastery of Surgery, 8e
Treatment
Treatment threshold: platelet count < 20-30 × 10⁹/L or any active bleeding, regardless of count.
First-Line Therapy
| Agent | Mechanism | Notes |
|---|---|---|
| Oral corticosteroids (prednisone 1-1.5 mg/kg/day) | Decrease platelet clearance; increase production | Response in 50-75% within 3 weeks; relapses common; avoid prolonged use |
| IVIG (1 g/kg x 1-2 doses) | Competes for Fcγ receptors on macrophages, reducing platelet clearance | For active/severe bleeding, pre-operative use, steroid failure/contraindication; rapid but not sustained response |
| Anti-D immunoglobulin | Causes mild hemolysis, saturating Fcγ receptors | Only in Rh-positive, non-splenectomized patients |
Second-Line Therapy
| Agent | Response Rate | Notes |
|---|---|---|
| Splenectomy | Complete 66%, overall 88% | Recommended after 12-24 months; long-term remission in 75-85%; laparoscopic approach preferred |
| Rituximab (anti-CD20) | Initial 60-63%; drops to 20-31% at 1-2 years | B-cell depletion; severe toxicity in 2-6% |
| TPO Receptor Agonists - romiplostim, eltrombopag | ~80% | Mimic endogenous TPO; stimulate megakaryocyte growth; maintenance therapy; significant advance since 2008 |
| Fostamatinib (spleen tyrosine kinase inhibitor) | Moderate | For refractory disease |
| Immunosuppressants (azathioprine, cyclophosphamide, mycophenolate) | Variable | Third-line options |
- Schwartz's Principles of Surgery, 11e; Fischer's Mastery of Surgery, 8e
Third-Line / Refractory ITP
- Combination of first and second-line therapies
- Combination chemotherapy
- Clinical trials
Splenectomy in ITP - Key Points
-
Indication: Failure/dependence on steroids (> 10-20 mg/day for 3-6 months to maintain platelet > 30,000), relapse, chronic ITP > 12-24 months, life-threatening bleeding
-
Mechanism: Removes the primary site of both autoantibody production and platelet destruction
-
Outcome: Permanent response without steroids in 75-85%; complete response (66%), partial (22%)
-
Approach: Laparoscopic splenectomy is now the standard; comparable long-term outcomes to open surgery with better short-term results
-
Pre-op: Vaccinate against encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis) at least 2 weeks before surgery
-
Complication: Risk of Overwhelming Post-Splenectomy Infection (OPSI) and increased thrombotic events
-
Children: Controversial - > 70% achieve complete remission without surgery; splenectomy generally deferred
-
Schwartz's Principles of Surgery, 11e; Current Surgical Therapy, 14e; Bailey and Love's, 28e
Pediatric vs. Adult ITP Summary
| Feature | Children (Acute ITP) | Adults (Chronic ITP) |
|---|---|---|
| Onset | Sudden, post-viral | Insidious |
| Age | Typically < 5 years | Females 15-50 most common |
| Sex ratio | Equal | Female predominance |
| Course | Self-limiting (> 70% remit spontaneously) | Chronic; relapses common |
| Splenectomy | Rarely indicated; controversial | Effective second-line option |
Recent Evidence Update (2024-2025)
A 2025 network meta-analysis (PMID 40196346) confirmed that TPO receptor agonists (romiplostim, eltrombopag) are highly effective and safe in adult ITP, with real-world data supporting their expanded use. A separate 2024 meta-analysis (PMID 38856778) found fostamatinib to be effective in refractory ITP. For pediatric ITP, a 2025 network meta-analysis (PMID 40547032) compared rhTPO, romiplostim, and eltrombopag, supporting TPO-RA use in children as well. These findings reinforce the trend of delaying splenectomy in favor of medical management.
This is a shared conversation. Sign in to Orris to start your own chat.